19 related articles for article (PubMed ID: 29101463)
1. A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma.
Dillon PM; Petroni GR; Horton BJ; Moskaluk CA; Fracasso PM; Douvas MG; Varhegyi N; Zaja-Milatovic S; Thomas CY
Clin Cancer Res; 2017 Aug; 23(15):4138-4145. PubMed ID: 28377480
[No Abstract] [Full Text] [Related]
2. Identification of the perpetrator imperatorin in Xin-yi-san-theophylline interaction: observed and predicted herb-drug interaction in rats.
Wang HJ; Chen AC; Chen HY; Cheng HC; Kao LT; Lu CK; Tsai KC; Lee IJ; Ueng YF
J Pharm Pharmacol; 2023 Sep; 75(9):1225-1236. PubMed ID: 37364866
[TBL] [Abstract][Full Text] [Related]
3. Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study.
Moreno I; Hernández T; Calvo E; Fudio S; Kahatt C; Fernández C; Iglesias JL; Corral G; Pérez-Ramos L; Montilla L; Zeaiter A; Lubomirov R
Pharmaceuticals (Basel); 2024 Jan; 17(2):. PubMed ID: 38399397
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.
Sarantopoulos J; Goel S; Chung V; Munster P; Pant S; Patel MR; Infante J; Tawbi H; Becerra C; Bruce J; Kabbinavar F; Lockhart AC; Tan E; Yang S; Carlson G; Scott JW; Sharma S
Cancer Chemother Pharmacol; 2016 Nov; 78(5):921-927. PubMed ID: 27681579
[TBL] [Abstract][Full Text] [Related]
5. A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).
Infante JR; Ramanathan RK; George D; Tan E; Quinlan M; Liu A; Scott JW; Sharma S
Cancer Chemother Pharmacol; 2015 Apr; 75(4):729-37. PubMed ID: 25648347
[TBL] [Abstract][Full Text] [Related]
6. The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors.
Sharma S; Britten CD; Mortimer J; Kulkarni S; Quinlan M; Liu A; Scott JW; George D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):867-74. PubMed ID: 25193431
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.
Kim KB; Chesney J; Robinson D; Gardner H; Shi MM; Kirkwood JM
Clin Cancer Res; 2011 Dec; 17(23):7451-61. PubMed ID: 21976540
[TBL] [Abstract][Full Text] [Related]
8. Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.
Dubbelman AC; Upthagrove A; Beijnen JH; Marchetti S; Tan E; Krone K; Anand S; Schellens JH
Cancer Chemother Pharmacol; 2012 Nov; 70(5):653-63. PubMed ID: 23010851
[TBL] [Abstract][Full Text] [Related]
9. A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors.
de Weger VA; Goel S; von Moos R; Schellens JHM; Mach N; Tan E; Anand S; Scott JW; Lassen U
Cancer Chemother Pharmacol; 2018 Jan; 81(1):73-80. PubMed ID: 29101463
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
DeVane CL; Gill HS
J Clin Psychiatry; 1997; 58 Suppl 5():7-14. PubMed ID: 9184622
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
